Tapering Opioids in Elderly COPD Patients

Introduction to Tapering

• A gradual taper over several weeks is recommended rather than an abrupt reduction, with slower tapers generally safer than rapid protocols, according to the Mayo Clinic Proceedings 1
• The current reduction from 12 mg/day to 8 mg/day represents a 33% dose reduction, which is reasonable but should be implemented gradually, as recommended by the Mayo Clinic Proceedings 1

Monitoring and Assessment

• Assess for signs of withdrawal, such as anxiety, restlessness, increased pain, and diaphoresis, during the taper, as suggested by the Mayo Clinic Proceedings 1
• Evaluate for adequate pain control and dyspnea management, as these are the likely indications for opioid therapy, according to Cardiovascular Research 2, 3, 4, 5

Clinical Context for Opioid Use

• Low-dose opioids have the strongest evidence for breathlessness management in stable COPD, with doses up to 30 mg/24h of oral morphine equivalent appearing unrelated to excess mortality or hospital admission, as reported by Cardiovascular Research 2, 3, 4, 5
• The current dose of 12 mg hydromorphone daily is approximately equivalent to 60 mg oral morphine daily, which is within the studied range, according to Cardiovascular Research 2, 3, 4, 5

Critical Considerations

• Beta-blocking agents, including eye drops, should be avoided in COPD patients as they can cause bronchoconstriction, as noted in Thorax 6, 7, 8, 9
• Ensure beta-blockers are not being used concurrently during the taper, as recommended by Thorax 6, 7, 8, 9